Aradhana Sarin
Executive Director and CFOAstraZeneca
PharmaceuticalsView Profile →Chief Financial Officer and Member of the Board of Management · Bayer
Judith Hartmann is Bayer’s chief financial officer, with earlier group finance and operational leadership at ENGIE and Bertelsmann and experience at General Electric and Disney.
Last reviewed: Nov 15, 2026
Judith Hartmann is Bayer’s chief financial officer, with earlier group finance and operational leadership at ENGIE and Bertelsmann and experience at General Electric and Disney.
Hartmann’s early career combined finance with international operating experience. After studying at the Vienna University of Economics and Business, she worked for the Walt Disney Company in Paris. She moved to General Electric in 2000, serving in financial and operational positions across Europe, the United States and Latin America, including its healthcare and energy businesses.
She became Bertelsmann’s group chief financial officer in 2012. In 2015, she moved to GDF SUEZ, subsequently known as ENGIE. She joined the group in February and assumed the deputy general management role responsible for finance on March 16.
At ENGIE, her responsibilities extended beyond financial reporting. Between 2016 and 2019 she also steered operations in the United Kingdom and North America. Her remit later included corporate social responsibility and procurement. From February through December 2020, she participated in the collegial management team responsible for the group’s interim operational leadership.
Hartmann became an operating partner at climate-infrastructure investor Sandbrook Capital in 2023. Her governance experience includes a Unilever non-executive directorship from 2015 to 2024. She also serves on Marsh’s board.
Bayer appointed her to its management board on March 1, 2026, ahead of the CFO succession scheduled for June 1. By the July 30 half-year responsibility statement she was a signatory of the board; Bayer’s current roster assigns her the Finance portfolio. The move brings experience from media, industrial technology, energy and infrastructure investment into a life-sciences group.